Exploring surrounding epigenetic influences in Ewing sarcoma
Dr Sara Sánchez Molina is investigating how a certain gene drives Ewing sarcoma in order to find a better way to treat it.
Exploring potential indicators of the likely course of disease: analysing blood samples from patients recruited to the rEECur clinical trial
Professor Martin McCabe aims to understand whether blood-based biomarkers could help predict Ewing sarcoma survival.
Understanding CaMK1D in diffuse large B cell lymphoma in children
Understanding how a protein affects the growth and development of lymphoma cells in order to build the foundations for safer and more effective treatments.
Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Detecting lingering brain cancer cells before a tumour grows back
Ependymoma comes back after treatment around half of the time, because some cancer cells are still alive. If doctors could identify these cells and diagnose relapsed ependymoma sooner, children could start treatment earlier.
Developing ways to identify chemotherapy resistant B-cell acute lymphoblastic leukaemia cells
Developing a test that can measure the amount of chemotherapy-resistant leukaemia cells in patient's blood samples. This would provide the foundations for future research.
Understanding how hospitals are offering chemotherapy infusions
Dr Jess Morgan at Leeds Children’s Hospital and Dr Gemma Bryan at University of Surrey hope to understand more about how hospitals are offering chemotherapy that needs to be given as infusions over a number of days.
How do DNA cutting errors lead to relapsed childhood leukaemia
Looking at how a process called 'cut-and-run' leads to genetic errors, and how those errors could be prevented in order to prevent relapse in childhood leukaemia.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.